Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/20669
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Urbancic, Karen F | - |
dc.contributor.author | Ierino, Francesco L | - |
dc.contributor.author | Phillips, E | - |
dc.contributor.author | Mount, Peter F | - |
dc.contributor.author | Mahony, Andrew A | - |
dc.contributor.author | Trubiano, Jason | - |
dc.date | 2017-10-03 | - |
dc.date.accessioned | 2019-04-15T05:39:54Z | - |
dc.date.available | 2019-04-15T05:39:54Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.citation | American Journal of Transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018; 18(2): 462-466 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/20669 | - |
dc.description.abstract | While trimethoprim-sulfamethoxazole is considered first-line therapy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug reactions may limit use and increase reliance on costly and less effective alternatives, often aerosolized pentamidine. We report our experience implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to optimize prophylaxis in this patient cohort. We retrospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis prior to and after protocol implementation. Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or during the prophylaxis period, of which 83% were non-immune-mediated and 17% were immune-mediated. Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol implementation (4/22 vs 23/27; P = .0001), with no recurrence of adverse drug reactions in 74%. In those who experienced a new or recurrent reaction (26%), all were mild and self-limiting with only 1 recurrence of an immune-mediated reaction. After protocol implementation, aerosolized pentamidine-associated costs were reduced. The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context of both prior immune and non-immune-mediated reactions was safe and successful in improving the uptake of first-line Pneumocystis pneumonia prophylaxis in renal transplant recipients. | en_US |
dc.language.iso | eng | - |
dc.subject | allergy | en_US |
dc.subject | antibiotic prophylaxis | en_US |
dc.subject | clinical research/practice | en_US |
dc.subject | desensitization | en_US |
dc.subject | drug toxicity | en_US |
dc.subject | infectious disease | en_US |
dc.subject | kidney transplantation/nephrology | en_US |
dc.subject | kidney transplantation: living donor | en_US |
dc.title | Taking the challenge: A protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | American Journal of Transplantation | en_US |
dc.identifier.affiliation | Pharmacy | en_US |
dc.identifier.affiliation | National Centre for Infections in Cancer, National Health and Medical Research Council Centre of Research Excellence, Peter MacCallum Cancer Centre, Department of Oncology, University of Melbourne, Parkville, VIC, Australia | en_US |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Parkville, VIC, Australia | en_US |
dc.identifier.affiliation | Nephrology | en_US |
dc.identifier.affiliation | Nephrology Department, St Vincent's Hospital, Melbourne, VIC, Australia | en_US |
dc.identifier.affiliation | Infectious Diseases | en_US |
dc.identifier.affiliation | Infectious Diseases Department, Vanderbilt University Medical Center, Nashville, TN, USA | en_US |
dc.identifier.doi | 10.1111/ajt.14498 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-9275-578X | en_US |
dc.identifier.orcid | 0000-0001-7637-3661 | en_US |
dc.identifier.pubmedid | 28898546 | - |
dc.type.austin | Journal Article | - |
dc.type.austin | Research Support, Non-U.S. Gov't | - |
local.name.researcher | Mahony, Andrew A | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | Nephrology | - |
crisitem.author.dept | Institute for Breathing and Sleep | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Infectious Diseases | - |
crisitem.author.dept | Infectious Diseases | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Centre for Antibiotic Allergy and Research | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.